Contact information
Type
Scientific
Contact name
Dr Wendy Spettigue
ORCID ID
Contact details
Psychiatric Director
Eating Disorder Program
Children's Hospital of Eastern Ontario
401 Smyth Road
Ottawa
K1H 8L1
Canada
wspettigue@cheo.on.ca
Additional identifiers
EudraCT/CTIS number
IRAS number
ClinicalTrials.gov number
Protocol/serial number
N/A
Study information
Scientific title
Acronym
Study hypothesis
It is hypothesised that youth who present with a severe eating disorder and are treated with olanzapine will demonstrate reduced disordered eating attitudes and beliefs, and a higher rate of weekly weight gain, as compared to a control group treated with placebo. It is also hypothesised that those patients treated with olanzapine will demonstrate better short-term (14 weeks) and long-term (6 months) clinical outcome as compared to patients treated with placebo. It is also predicted that the physical side-effects of olanzapine will be minor given the relatively lose dose (as compared to treatment for patients with schizophrenia), slow titration, and short-term use of olanzapine. Hospitalised patients on olanzapine may be discharged sooner than those on placebo.
Ethics approval(s)
Not provided at time of registration
Study design
Randomised controlled trial
Primary study design
Interventional
Secondary study design
Randomised controlled trial
Study setting(s)
Not specified
Study type
Treatment
Patient information sheet
Condition
Anorexia Nervosa
Intervention
Olanzapine versus Placebo; Olanzapine will be started at a very low dose and gradually titrated up to a predetermined dose.
Intervention type
Drug
Pharmaceutical study type(s)
Phase
Not Specified
Drug/device/biological/vaccine name(s)
Olanzapine
Primary outcome measure
The change from baseline in the Eating Attitudes Test (EAT-26) score measured at week 12 and average weight gain over the first 12 weeks of treatment will be compared using Students t-test (assuming a normal distribution of the measures; otherwise, Wilcoxon Mann Whitney test will be used). If necessary, a linear regression model will be fit to assess treatment effect adjusting for variables thought to influence outcome that could result in imbalance between treatment groups at baseline. Treatment effect and its 95% confidence interval will be generated for each primary outcome.
Secondary outcome measures
Although the study is not powered to detect differences in safety, we will nevertheless compare the frequency of adverse events between the two study groups using chi-square or Fishers exact test. Change from baseline in the EAT-26 score measured at week 15 and at the end of the maintenance period (week 40) as well as weight gain measured at the same time points will be analysed as for the primary outcomes. Change from baseline in the Computer Assisted Personal Interview (CAPI), Childrens Depression Inventory (CDI), Multidimensional Anxiety Scale for Children (MASC), the Eating Disorder Clinician-Parent Rating Sheet, and Child Behavior Checklist (CBCL) will be calculated for weeks 12 and 40. Assuming a normal distribution for each variable (except for the clinician/parent rating sheet), differences between study groups will be assessed using Students t-tests. Wilcoxon Mann-Whitney tests or log-transformation will be performed otherwise. The Eating Disorder Clinician/Parent Rating Sheet score will also be compared using a Wilcoxon Mann-Whitney test. A Poisson regression model will be used to compare the total number of hospital admissions between study groups. Rate of hospitalisation will be calculated for each patient as the total number of days in hospital divided by the total time in days spent in the study. Average rates and 95% confidence intervals will be generated for each study group. Rates will then be compared using a Poisson regression model. In order to avoid multiple testing issues, results will be compared with an alpha value adjusted for the number of tests performed using the Bonferonni criterion.
Overall study start date
01/09/2005
Overall study end date
01/09/2007
Reason abandoned (if study stopped)
Eligibility
Participant inclusion criteria
1. Must give written informed consent or assent
2. Must be female
3. Must be between age 12 and 17 (younger than 18) at beginning of trial
4. Based on the Diagnostic and Statistical Manual of Mental Disorders (4th Edition Revised, American Psychiatric Association [APA], 2000) must have fulfilled the criteria for diagnosis of Anorexia Nervosa or Eating Disorder Not Otherwise Specified with a Body Mass Index ≤17
Participant type(s)
Patient
Age group
Child
Lower age limit
12 Years
Upper age limit
17 Years
Sex
Female
Target number of participants
50 subjects; 25 intervention, 25 control
Participant exclusion criteria
1. Subject has known sensitivity to any of the products to be administered
2. Treatment with any other anti-psychotic medication, mood stabiliser, stimulant
3. Treatment with medication known to interact with olanzapine e.g. fluvoxamine, ciprofloxacin
4. Medical illness such as: diabetes, impaired glucose tolerance, hyperlipidemia, hepatic dysfunction, substance abuse, narrrow angle glaucoma, paralytic ileus, or pancreatitis
5. Subjects inability to comply with trial requirements including lack of comprehension of English
6. Other unspecified reasons that, in the opinion of the Investigator, make subject unsuitable for enrollment
7. Subject is pregnant or is breast-feeding
8. Laboratory exclusion criteria:
a. Total white cell count <2.5
b. Neutrophil count <1.0
c. Liver function tests (aspartate transaminase (AST)/alanine transaminase (ALT) >2 X normal)
d. Positive pregnancy test
e. Electrocardiogram (EKG) QTc >440 msec or arrythmia other than sinus bradycardia; conduction abnormalities prolonged QTc or other
Recruitment start date
01/09/2005
Recruitment end date
01/09/2007
Locations
Countries of recruitment
Canada
Study participating centre
Psychiatric Director
Ottawa
K1H 8L1
Canada
Sponsor information
Organisation
Children's Hospital of Eastern Ontario (Canada)
Sponsor details
401 Smyth Road
Ottawa
K1H 8L1
Canada
+1 613 737 7600
wspettigue@cheo.on.ca
Sponsor type
Hospital/treatment centre
Website
ROR
Funders
Funder type
Charity
Funder name
W. Garfield Weston Foundation (Canada)
Alternative name(s)
The W. Garfield Weston Foundation
Funding Body Type
private sector organisation
Funding Body Subtype
Trusts, charities, foundations (both public and private)
Location
Canada
Results and Publications
Publication and dissemination plan
Not provided at time of registration
Intention to publish date
Individual participant data (IPD) sharing plan
IPD sharing plan summary
Not provided at time of registration
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Protocol article | protocol | 31/01/2008 | Yes | No |